作者
Jakub Kucharz, Agnieszka Giza, Paulina Dumnicka, Marek Kuzniewski, Beata Kusnierz-Cabala, Pawel Bryniarski, Roma Herman, Aneta Lidia Zygulska, Krzysztof Krzemieniecki
发表日期
2016/10
期刊
Medical Oncology
卷号
33
页码范围
1-7
出版商
Springer US
简介
Sunitinib, a multi-targeted receptor tyrosine kinase inhibitor, is a first-line treatment for metastatic renal cell carcinoma (mRCC) in patients in ‘low’ and ‘intermediate’ Memorial Sloan Kettering Cancer Center and Heng risk groups. Disruptions of hematopoiesis, such as anemia, neutropenia, and thrombocytopenia, are typically observed during sunitinib treatment. When it comes to RBC parameters, an increase in mean cell volume (MCV) tends to occur, meeting the criteria for macrocytosis in some patients (MCV > 100 fL). We examined changes in RBC parameters of 27 mRCC patients treated with sunitinib (initial dose of 50 mg/day, 6-week treatment: 4 weeks on, 2 weeks off) and correlated them with progression-free survival time (PFS). Patients who had macrocytosis after 3 treatment cycles had significantly longer PFS than those whose MCV stayed less than 100 fL (not reached vs. 11.2 months, p < 0.001 …
学术搜索中的文章
J Kucharz, A Giza, P Dumnicka, M Kuzniewski… - Medical Oncology, 2016